Veracyte, Inc. last reported quarterly results on Nov 4, 2026, for Q3 FY2026 (the quarter ended Sep 30, 2026): revenue of $151.8 million (+15.1% year over year) and diluted EPS of $0.38. It usually reports 12–35 days after a quarter ends. Based on that pattern, the next release is estimated for around Jan 11, 2027.
Results for Q4 FY2026, the quarter ending around Dec 31, 2026. Expected on a Monday. Based on last year's release for the same quarter on Jan 12, 2026. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 12–35 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Nov 4, 2026
35 days after quarter end
|
Q3 FY2026
ended Sep 30, 2026
|
152
+15.1%
|
32
+64.6%
|
0.38
+58.3%
|
|
Jul 30, 2026
30 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
150
+15.5%
|
25
+2701.0%
|
0.31
+3200.0%
|
|
May 5, 2026
35 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
139
+21.5%
|
29
+307.4%
|
0.35
+288.9%
|
|
Jan 12, 2026
12 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
141
+18.5%
|
41
+704.8%
|
0.50
+687.0%
|
|
Nov 4, 2025
35 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
132
+13.8%
|
19
+26.3%
|
0.24
+26.3%
|
|
Aug 6, 2025
37 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
130
+13.8%
|
-1
-117.1%
|
-0.01
-114.3%
|
|
May 7, 2025
37 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
114
+18.2%
|
7
+478.1%
|
0.09
+550.0%
|
|
Feb 24, 2025
55 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
119
+20.8%
|
5
+118.1%
|
0.06
+116.4%
|
Company profile
- Industry
- Services-Medical Laboratories (SIC 8071)
- Listed as
- VCYT (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- South San Francisco, CA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1384101
- Former names
- CALDEROME INC (until Feb 27, 2008)
Other Services-Medical Laboratories companies
- Natera, Inc. NTRA
- Labcorp Holdings Inc. LH
- Quest Diagnostics Inc DGX
- Guardant Health, Inc. GH
- Caris Life Sciences, Inc. CAI
- GRAIL, Inc. GRAL
- RadNet, Inc. RDNT
- BillionToOne, Inc. BLLN
Source: SEC EDGAR filings. This is company-reported data, not investment advice.